ERBB2 and breast cancer: Even though the predicted efficacy of trans-(−)-kusunokinin seemed unable to compete with the irreversible inhibitor (neratinib), the drug-associated drawbacks have left room for further investigation into the anticancer effect of synthetic (±)-kusunokinin based on HER2 and HER2 related proteins in breast cancer.